title: [Case of a patient with inflammatory breast cancer who responded to preoperative chemotherapy with paclitaxel plus bevacizumab and could subsequently undergo surgery].
abstract: A 58-year-old woman observed swelling in her left breast a few weeks prior to presentation. Rigidity in the D area, breast warmth, swelling, and a peau d'orange appearance in the whole left breast was observed. She was diagnosed with inflammatory breast cancer (luminal A type) T4dN2M0, Stage IIIB. The patient underwent primary systemic therapy with 7 courses of FEC. Following FEC treatment, the disease was stable. We subsequently administered 4 courses of bevacizumab plus paclitaxel combination therapy. The patient exhibited a partial response to FEC chemotherapy. Thereafter, a left mastectomy with level II axillary lymph node dissection was performed. At present, 1 year after surgery, the patient is alive with no recurrence. We conclude that the combination therapy of bevacizumab plus paclitaxel is a useful treatment for inflammatory breast cancer.
authors.affiliation: Dept. of Surgical Oncology, Osaka City University Graduate School of Medicine.
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Kashiwagi
authors.forename: Sae
authors.initials: S
authors.lastname: Ishihara
authors.forename: Mariko
authors.initials: M
authors.lastname: Ishii
authors.forename: Yuka
authors.initials: Y
authors.lastname: Asano
authors.forename: Mao
authors.initials: M
authors.lastname: Watanabe
authors.forename: Tamami
authors.initials: T
authors.lastname: Morisaki
authors.forename: Naoki
authors.initials: N
authors.lastname: Aomatsu
authors.forename: Satoru
authors.initials: S
authors.lastname: Noda
authors.forename: Hidemi
authors.initials: H
authors.lastname: Kawajiri
authors.forename: Taeko
authors.initials: T
authors.lastname: Nakano
authors.forename: Noriko
authors.initials: N
authors.lastname: Kawakami
authors.forename: Yasuko
authors.initials: Y
authors.lastname: Mitsukawa
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Takashima
authors.forename: Naoyoshi
authors.initials: N
authors.lastname: Onoda
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Ishikawa
authors.forename: Kosei
authors.initials: K
authors.lastname: Hirakawa
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000601:surgery; D005260:Female; D006801:Humans; D058922:Inflammatory Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D008408:Mastectomy; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D017239:Paclitaxel / Q000008:administration & dosage
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D017239:Paclitaxel